{
    "organizations": [],
    "uuid": "9dbff3548d9349822b44e853925d0863c2022382",
    "author": "",
    "url": "https://www.reuters.com/article/brief-lycera-corp-announces-initiation-o/brief-lycera-corp-announces-initiation-of-phase-1b-study-of-novel-immuno-oncology-candidate-lyc-55716-in-combination-with-pembrolizumab-idUSFWN1OZ0NB",
    "ord_in_thread": 0,
    "title": "BRIEF-Lycera Corp Announces Initiation Of Phase 1b Study Of Novel Immuno-Oncology Candidate LYC-55716 In Combination With Pembrolizumab",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 4, 2018 / 1:49 PM / Updated 8 minutes ago BRIEF-Lycera Corp Announces Initiation Of Phase 1b Study Of Novel Immuno-Oncology Candidate LYC-55716 In Combination With Pembrolizumab Reuters Staff 1 Min Read \nJan 4 (Reuters) - Merck & Co Inc: \n* LYCERA CORP ANNOUNCES INITIATION OF PHASE 1B STUDY OF NOVEL IMMUNO-ONCOLOGY CANDIDATE LYC-55716 IN COMBINATION WITH PEMBROLIZUMAB Source text for Eikon: Further company coverage:",
    "published": "2018-01-04T15:47:00.000+02:00",
    "crawled": "2018-01-04T16:11:46.007+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "updated",
        "minute",
        "ago",
        "corp",
        "announces",
        "initiation",
        "phase",
        "1b",
        "study",
        "novel",
        "candidate",
        "combination",
        "pembrolizumab",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "merck",
        "co",
        "inc",
        "lycera",
        "corp",
        "announces",
        "initiation",
        "phase",
        "1b",
        "study",
        "novel",
        "candidate",
        "combination",
        "pembrolizumab",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}